{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"48.3","value":"971"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Maximum (peak) observed plasma concentration after dose administration (mass x volume-1).","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants randomized to asciminib 40mg BID","id":"OG000","title":"Asciminib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) analysis set (PAS) included all participants who provided at least one evaluable PK concentration.","reportingStatus":"POSTED","timeFrame":"Week 2 Day 1 at pre-dose, 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose","title":"PK Parameter: Cmax for Asciminib","type":"SECONDARY","unitOfMeasure":"ng/mL"}